Donaldson Company (DCI) Q3 2024 earnings summary

Executive summary

• Achieved record third quarter sales of $928 million, up 6% year-over-year, with EPS up 21.7% to $0.92 and operating margin at a decade-long high, driven by growth across all segments, especially Life Sciences and Mobile Solutions.

• All segments delivered growth and profitability, with notable strength in aftermarket and bioprocessing businesses, despite mixed end-market conditions.

• Gross margin improved to 35.6%, up 260 basis points year-over-year, supported by higher sales, pricing actions, and input cost deflation.

• Continued investments in innovation, acquisitions, and sustainability, with $57 million returned to shareholders via dividends and buybacks.

• Backlogs remain strong and supply chain conditions are supportive, indicating continued business health.

Financial highlights

• Q3 sales reached $928 million, up 6% year-over-year, with pricing contributing 2%.

• Operating income rose 16%, gross margin expanded to 35.6%, and operating margin increased to 15.5%.

• Diluted EPS rose 21.7% to $0.92; net earnings for Q3 were $113.5 million, up 21.1%.

• Free cash flow for the quarter was $120.2 million, with cash conversion at 106%.

• Net debt to EBITDA ended at 0.5x; total debt to capitalization was 27.3% at quarter end.

Outlook and guidance

• Full-year sales guidance narrowed to 4%-6% growth, with pricing benefit of 2% and minimal currency impact.

• EPS guidance raised to $3.33–$3.39, with operating margin guidance of 15.0%-15.4%.

• Mobile Solutions sales expected to rise 2%-4%; Industrial Solutions outlook raised to 6%-8% growth; Life Sciences sales guidance reduced to mid-teens growth.

• Cash conversion forecast at 95%-105%; capital expenditures projected at $90-$105 million.

• Management expects sufficient liquidity to meet all cash requirements for the next 12 months and beyond.